Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
129
datasets available to search
ShareScore release 0.9.0
Dataset results
129 results for “blood lipid”
Raw data to "Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction"
<p>Background: Lack of resolution of inflammation may be considered a critical player for the onset and progression of multiple sclerosis. To demonstrate this we extracted lipids from plasma samples of healthy donors and MS patients and we quantified over 65 lipid mediators (LMs) through LC-MS-MS using signature diagnostic ions via multiple reaction monitoring.</p> <p>Results: Out of the 65 lipid mediators analyzed, only 42 were detected and out of those only 27 were finally revealed to show differences between healthy subjects and MS patients. These 27 LMs belonged to the arachidonic (AA), docosahexaenoic (DHA) or eicosapentaenoic (EPA) acid metabolomes and we could clusterize each form of MS into a specific profile by means of principal component analysis. Altogether, compared to healthy subjects, MS patients showed a strong production of several AA-derived eicosanoids (i.e. PGE2, PGD2 and PGF2a) (Fig.1D) and a little production of two DHA-derived pro-resolving mediators (SPMs), i.e. Protectin D1 (D1) and protectin DX (PDX) (Fig.1A). However, no production of DHA-derived resolvins and maresins (Fig. 1B) as well as EPA-derived resolvins (Fig.1 C) was observed.</p> <p>When stratifying MS patients according to disease form, both relapsing MS patients showed production of only two pro-resolving mediators (SPMs), i.e. Resolvin D1 (RvD1) and Protectin D1 (D1) compared to healthy subjects, whereas remitting MS patients showed a production of only few AA- and DHA-derived metabolic pathway markers and progressive MS patients a strong production of several eicosanoids as well as other metabolic pathway markers.</p> <p>Conclusions: These data suggest that along disease progression, there is a lack of production of anti-inflammatory and pro-resolving lipid mediators associated to a higher production of pro-inflammatory ones.</p>
Amines and lipids metabolites in blood plasma and saliva samples in pigs.
<p>The dataset presented in here is generated in a project named "<strong>Effects of sanitary and health status on amino acid and energy metabolism of growing-finishing pigs.</strong>" The metabolomics data from two samples types in pigs were generated in collaboration with Metabolomics Facility Leiden, The Netherlands and Wageningen Livestock Research, The Netherlands. This collaboration was realized and funded by Enabling Technology Hotels programme, ZonMW, NWO, The Netherlands (<strong>project number: 435005015</strong>). </p> <p>Targeted quantification of metabolites in two metabolomic platforms covering amines and oxidative stress metabolites in the blood and saliva samples in pigs. The samples were collected from a feeding trial. Briefly, After weaning, i.e., at week 4, pigs were fed a starter (4-9 weeks), grower (9-14 weeks), and finisher (14-22 weeks) diet containing either starch or fat as an energy source. At week 9, before the pigs were fed the grower diet, blood plasma and saliva samples were collected from the pigs (n=6) and the animals were stratified according to different hygiene conditions. At week 14, i.e., before the pigs received the finisher diet, and at week 22, i.e., at the end of this experiment, blood plasma and saliva samples were collected from the pigs (n=6) in the cohort receiving a diet with a different energy source under contrasting sanitary status. </p> <p>Targeted quantification of metabolites in two metabolomic platforms covering amines and oxidative stress metabolites in the blood and saliva samples in pigs. The number of identified metabolites are shown in Table 1.</p> <p><strong>Table 1</strong>: <strong>Number of identified amines and lipids metabolites in blood plasma and saliva samples in pigs.</strong> </p> <table> <tbody> <tr> <td> <table align="center"> <tbody> <tr> <td> <p> </p> </td> <td> <p>Data reported as</p> </td> </tr> <tr> <td> </td> <td> <p>Peak areas<sup>1</sup></p> </td> <td> <p>Relative response ratios<sup>4</sup></p> </td> </tr> <tr> <td> <p> </p> </td> <td> <p>Confidence<sup>2</sup></p> </td> <td> <p>Caution<sup>3</sup></p> </td> <td> <p>Confidence</p> </td> <td> <p>Caution</p> </td> </tr> <tr> <td> <p><em>Amines</em></p> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <p>Blood plasma</p> </td> <td> <p>not required</p> </td> <td> <p>not required</p> </td> <td> <p>58</p> </td> <td> <p>2</p> </td> </tr> <tr> <td> <p>Saliva</p> </td> <td> <p>not required</p> </td> <td> <p>not required</p> </td> <td> <p>52</p> </td> <td> <p>5</p> </td> </tr> <tr> <td> <p><em>Lipids </em></p> <p><em>(low pH)</em></p> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <p>Blood plasma</p> </td> <td> <p>47</p> </td> <td> <p>17</p> </td> <td> <p>47</p> </td> <td> <p>17</p> </td> </tr> <tr> <td> <p>Saliva</p> </td> <td> <p>18</p> </td> <td> <p>34</p> </td> <td> <p>52</p> </td> <td> <p>11</p> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <p><em>Lipids </em></p> <p><em>(High pH)</em></p> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <p>Blood plasma</p> </td> <td> <p>24</p> </td> <td> <p>25</p> </td> <td> <p>24</p> </td> <td> <p>25</p> </td> </tr> <tr> <td> <p>Saliva</p> </td> <td> <p>28</p> </td> <td> <p>17</p> </td> <td> <p>28</p> </td> <td> <p>17</p> </td> </tr> </tbody> </table> <p> </p> </td> </tr> </tbody> </table> <p></p> <p><sup>1</sup> For the lipid platform, large variations in internal standard were observed between study samples. This could be due to the difference in matrix effect between the study samples, i.e., blood plasma and saliva. It is known that the matrix effect varies significantly depending on the origin of the samples and is influenced by phenotypic characteristics such as species, age, and gender. Therefore, peak areas were provided as an additional data set that can be used as input data for downstream metabolomics analysis.</p> <p><sup>2</sup> Metabolite signaling complied with the acceptance criteria of RSDqc <15%.</p> <p><sup>3</sup> Metabolite signaling did not comply with the acceptance criteria of our quality control i.e. of RSDqc <15%, but they present RSDs up to 30%.</p> <p><em><sup>4</sup> </em>target area/ISTD area; unit free<em>.</em> </p> <p>Available data-set:</p> <p>-Four different signaling lipids data-set: 1) peak areas for plasma samples, 2) peak area ratios (metabolite to ISTD) for plasma samples, 3) peak areas for saliva samples, and 4) peak area ratios (metabolite to ISTD) for saliva samples.</p> <p> - Two signalling amine data-set: 1) peak area ratios (metabolite to ISTD) for plasma samples, and 2) peak area ratios (metabolite to ISTD) for saliva samples.</p> <p> </p>
The expressivity of rare coding variants for blood lipids in over a million individuals
<p>The supplemental data and codes for Koyama et al. "The expressivity of rare coding variants for blood lipids in over a million individuals"</p>
APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population
<p>In post-industrial settings, <i>APOE4</i> is associated with increased cardiovascular and neurological disease risk. However, the majority of human evolutionary history occurred in environments with higher pathogenic diversity and low cardiovascular risk. We hypothesize that in high-pathogen and energy-limited contexts, the <i>APOE4</i> allele confers benefits by reducing innate inflammation when uninfected, while maintaining higher lipid levels that buffer costs of immune activation during infection. Among Tsimane forager-farmers of Bolivia (N=1266), <i>APOE4</i> is associated with 30% lower C-reactive protein, and higher total cholesterol and oxidized-LDL. Blood lipids were either not associated, or negatively associated with inflammatory biomarkers, except for associations of oxidized-LDL and inflammation which were limited to high BMI adults. Further, <i>APOE4</i> carriers maintain higher levels of total and LDL cholesterol at low BMIs. These results suggest the relationship between <i>APOE4</i> and lipids may be beneficial for pathogen-driven immune responses, and unlikely to increase cardiovascular risk in an active subsistence population.</p>
An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment
ClinicalTrials.gov study NCT05398393. IPD Sharing: YES. Countries: 1. Publications: 4.
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
ClinicalTrials.gov study NCT00757783. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
ClinicalTrials.gov study NCT00300456. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity
ClinicalTrials.gov study NCT05210023. IPD Sharing: NO. Countries: 1. Publications: 9.
Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood
ClinicalTrials.gov study NCT00300482. IPD Sharing: Not stated. Countries: 1. Publications: 6.
Effect of Spirulina Maxima and Exercise on General Fitness and Blood Lipids in Older Adults
ClinicalTrials.gov study NCT04658875. IPD Sharing: NO. Countries: 1. Publications: 25.
Effect of Stevia Leave Powder on Blood Glucose and Lipid Profile of Diabetic Patients
ClinicalTrials.gov study NCT06645002. IPD Sharing: NO. Countries: 1. Publications: 1.
Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
ClinicalTrials.gov study NCT00300469. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Observation of Blood Lipid Outcomes in Lipid Clinic
ClinicalTrials.gov study NCT04220164. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Level
ClinicalTrials.gov study NCT00616772. IPD Sharing: Not stated. Countries: 1. Publications: 1.
APOE4 is associated with elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population
Open the record for dataset details and reuse information.
A multi-ethnic epigenome-wide association study of leukocyte DNA methylation and blood lipids
Open the record for dataset details and reuse information.
Effects of Lactobacillus plantarum Q180 on blood lipid levels and intestinal microbiota : a double-blind, randomized, placebo-controlled, parallel trial
<p>Probiotics can improve the intestinal environment by enhancing beneficial bacteria to potentially regulate lipid levels; however, the underlying mechanisms remain unclear. The aim of this study was to investigate the effect of <em>Lactobacillus plantarum</em> Q180 (LPQ180) on blood lipid levels and the intestinal microbiome environment from a clinical perspective. A double-blind, randomized, placebo-controlled study was conducted including 70 participants of both sexes, 20 years of age and older, with blood triacylglyceride (TG) levels below 200 mg/dL. Treatment with LPQ180 for 12 weeks significantly decreased LDL-cholesterol (<em>p</em> = 0.042) and apolipoprotein (Apo)B-100 (<em>p</em> = 0.003) levels, and decreased postprandial maximum concentrations (C<sub>max</sub>) and areas under the curve (AUC) of TG, chylomicron TG, ApoB-48, and ApoB-100. LPQ180 treatment significantly decreased total indole and phenol levels (<em>p</em> = 0.019). In addition, there was a negative correlation between baseline microbiota abundance and lipid marker change, which was negatively correlated with metabolites related to harmful bacteria. LPQ180 treatment may help prevent hypertriglyceridemia by improving fasting and postprandial blood lipid levels. In addition, LPQ180 effectively prevented the growth of harmful bacteria, particularly in subjects with higher baseline levels of harmful gut microbiota. Probiotics can improve the intestinal environment by enhancing beneficial bacteria to potentially regulate lipid levels; however, the underlying mechanisms remain unclear. The aim of this study was to investigate the effect of <em>Lactobacillus plantarum</em> Q180 (LPQ180) on blood lipid levels and the intestinal microbiome environment from a clinical perspective. A double-blind, randomized, placebo-controlled study was conducted including 70 participants of both sexes, 20 years of age and older, with blood triacylglyceride (TG) levels below 200 mg/dL. Treatment with LPQ180 for 12 weeks significantly decreased LDL-cholesterol (<em>p</em> = 0.042) and apolipoprotein (Apo)B-100 (<em>p</em> = 0.003) levels, and decreased postprandial maximum concentrations (C<sub>max</sub>) and areas under the curve (AUC) of TG, chylomicron TG, ApoB-48, and ApoB-100. LPQ180 treatment significantly decreased total indole and phenol levels (<em>p</em> = 0.019). In addition, there was a negative correlation between baseline microbiota abundance and lipid marker change, which was negatively correlated with metabolites related to harmful bacteria. LPQ180 treatment may help prevent hypertriglyceridemia by improving fasting and postprandial blood lipid levels. In addition, LPQ180 effectively prevented the growth of harmful bacteria, particularly in subjects with higher baseline levels of harmful gut microbiota.</p>
Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis
ClinicalTrials.gov study NCT00407641. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Effect of Diet Composition on Performance, Expenditure, Blood Lipids, and Appetite Hormones in Highly Trained Cyclists
ClinicalTrials.gov study NCT04097171. IPD Sharing: YES. Countries: 1. Publications: 1.
Whey Protein Comparisons for Blood Lipid Effects
ClinicalTrials.gov study NCT07101263. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.